Shareholders of the British company are set to receive 595 pence per share, representing a 59% premium over the stock's value prior to the disclosure of takeover talks in mid-May. Following the announcement, Tate & Lyle shares rose 11% to 544 pence. The merger will combine the owner of the Splenda sweetener brand with Ingredion, aiming to capitalize on the growing demand for healthier, lower-sugar, and high-protein food additives.

Beyond product development, the companies are positioning themselves to address shifts in consumer behavior linked to the rise of GLP-1 weight-loss medications, which often alter appetite and taste perception. The combined entity targets $130 million in cost synergies by 2030 and anticipates a 15% boost to earnings starting in the first year of operations. Tate & Lyle Chairman David Hearn stated that the partnership provides the scale and investment capacity necessary to accelerate innovation for customers. This acquisition marks the end of the firm's 87-year tenure on the London Stock Exchange, further highlighting the ongoing trend of foreign entities acquiring established British household names.